A Prospective Multicenter Phase 2 Study of FCR/BR Alternating With Ibrutinib in Treatment-naive Patients With CLL
Status:
Recruiting
Trial end date:
2027-12-30
Target enrollment:
Participant gender:
Summary
This is a prospective multicenter phase 2 study designed with the purpose to evaluate the
response rate and safety of treatment with FCR/BR alternating with ibrutinib in
treatment-naive patients with chronic lymphocytic leukemia.